Appropriate method for testing for cytomegalovirus (CMV) infection in a newborn blood sample when maternal CMV infection occurred during pregnancy: Diagnosis of congenital CMV infection requires virological confirmation within the first 2-3 weeks of life to distinguish congenital infection from postnatal acquisition. The gold standard for confirming congenital CMV infection is detection of CMV DNA by nucleic acid amplification tests (NAAT), primarily polymerase chain reaction (PCR), in urine samples collected within the first 3 weeks of life NHS Cytomegalovirus (C Leber 2024. Although a blood (plasma or dried blood spot) CMV PCR test may confirm cCMV diagnosis, it is less sensitive than urine PCR and is not generally recommended as the first-line diagnostic specimen NHS Cytomegalovirus (C Harrison et al. 2026.
Saliva samples are commonly used for early CMV detection due to ease of collection and high viral load, but positive saliva PCR results in newborns exposed to CMV-seropositive breast milk can be confounded by virus contamination from colostrum or breast milk, rendering saliva testing less specific for congenital infection in breastfed infants. Thus, saliva PCR is not recommended to definitively rule in or out CMV infection in newborns, especially if breastfed NHS Cytomegalovirus (C Harrison et al. 2026.
Therefore, while urine and saliva samples are important specimens for CMV testing in newborns, urine PCR within the first 3 weeks is considered the mainstay for confirming congenital CMV infection and ruling out CMV infection NHS Cytomegalovirus (C Leber 2024 Harrison et al. 2026. Blood sampling alone is inadequate to exclude infection due to lower sensitivity NHS Cytomegalovirus (C Leber 2024.
In summary, the appropriate approach when the mother had CMV infection during pregnancy is to perform viral DNA PCR testing on the newborn's urine sample collected within the first 21 days after birth for confirmation of congenital CMV infection. Saliva testing may help early detection but requires cautious interpretation due to possible contamination from breast milk. Blood samples may be tested but are less sensitive. Testing beyond 3 weeks risks detecting postnatal infection rather than congenital infection NHS Cytomegalovirus (C Leber 2024 Harrison et al. 2026.
Key References
- NHS: Cytomegalovirus (CMV)
- NICE CKS: Parvovirus B19 infection
- SmPC: Ganciclovir 500mg powder for Solution for Infusion vial
- NICE CKS: Hepatitis B
- NICE CKS: Bacterial vaginosis
- NICE NG195: Neonatal infection: antibiotics for prevention and treatment
- SmPC: Cymevene_500mg_powder-for-concentrate-for-solution-for-infusion
- SmPC: Cytotect CP Biotest
- (Şahiner, 2020): [Current Approaches in the Diagnosis and Management of Congenital Cytomegalovirus Infections and the Situation in Turkey].
- (Nicloux et al., 2020): Outcome and management of newborns with congenital cytomegalovirus infection.
- (Leber, 2024): Maternal and congenital human cytomegalovirus infection: laboratory testing for detection and diagnosis.
- (Fernandes et al., 2025): Postnatal Cytomegalovirus Infection in a Neonatal Intensive Care Unit: A Retrospective Study.
- (Arcieri et al., 2026): Antenatal Imaging and Neonatal Outcome in Infants with Congenital Cytomegalovirus Infection: The Effect of Valaciclovir.
- (Harrison et al., 2026): The Management of Congenital Cytomegalovirus Infection in an Era of Universal Newborn CMV Screening